Cogent Biosciences, Inc. (COGT) Current Ratio
- Current ratio · latest quarter: Value 13.57×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.57× | Current assets / current liabilities. $804.82M ÷ $59.30M ≈ 13.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 804.82M USD | Assets, Current |
| Current obligations | 59.30M USD | Liabilities, Current |
| Cash and equivalents | 181.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 611.13M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 7.49M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $804.82M | $59.30M | $181.17M | $611.13M | (m) | (m) | $7.49M | (m) | 13.57× |
| 2026-03-31 | $877.80M | $57.98M | $241.21M | $625.17M | (m) | (m) | $13.74M | (m) | 15.14× |
| 2025-12-31 | $910.36M | $63.95M | $312.01M | $588.75M | (m) | (m) | $9.50M | (m) | 14.23× |
| 2025-09-30 | $397.24M | $62.25M | $125.30M | $265.59M | (m) | (m) | $16.03M | (m) | 6.38× |
| 2025-06-30 | $245.01M | $58.42M | $127.60M | $110.25M | (m) | (m) | $16.63M | (m) | 4.19× |
| 2025-03-31 | $252.88M | $49.32M | $126.00M | $119.66M | (m) | (m) | $14.15M | (m) | 5.13× |
| 2024-12-31 | $296.47M | $55.71M | $98.17M | $188.91M | (m) | (m) | $12.01M | (m) | 5.32× |
| 2024-09-30 | $341.53M | $53.05M | $97.05M | $238.47M | (m) | (m) | $15.06M | (m) | 6.44× |
| 2024-06-30 | $369.97M | $40.00M | $88.22M | $275.00M | (m) | (m) | $8.97M | (m) | 9.25× |
| 2024-03-31 | $441.90M | $36.69M | $215.80M | $219.94M | (m) | (m) | $15.56M | (m) | 12.05× |
| 2023-12-31 | $270.77M | $38.17M | $53.23M | $212.48M | (m) | (m) | $10.65M | (m) | 7.09× |
| 2023-09-30 | $285.95M | $34.72M | $86.81M | $192.23M | (m) | (m) | $9.87M | (m) | 8.24× |
| 2023-06-30 | $334.52M | $25.76M | $214.32M | $115.08M | (m) | (m) | $7.16M | (m) | 12.99× |
| 2023-03-31 | $226.27M | $21.12M | $160.70M | $59.57M | (m) | (m) | $4.17M | (m) | 10.71× |
| 2022-12-31 | $264.97M | $26.85M | $139.89M | $119.39M | (m) | (m) | $5.84M | (m) | 9.87× |
| 2022-09-30 | $296.42M | $23.55M | $140.57M | $148.53M | (m) | (m) | $4.09M | (m) | 12.59× |
| 2022-06-30 | $330.68M | $27.66M | $325.56M | (m) | (m) | (m) | $3.49M | (m) | 11.96× |
| 2022-03-31 | $194.73M | $17.88M | $191.05M | (m) | (m) | (m) | $4.01M | (m) | 10.89× |
| 2021-12-31 | $222.63M | $17.08M | $219.68M | $0.00 | (m) | (m) | $3.48M | (m) | 13.04× |
| 2021-09-30 | $207.50M | $16.71M | $202.89M | (m) | (m) | (m) | $4.35M | (m) | 12.42× |
| 2021-06-30 | $221.35M | $13.68M | $218.10M | (m) | (m) | (m) | $1.99M | (m) | 16.18× |
| 2021-03-31 | $232.07M | $8.24M | $230.74M | (m) | (m) | (m) | $315.00K | (m) | 28.16× |
| 2020-12-31 | $244.91M | $13.09M | $242.19M | (m) | (m) | (m) | $732.00K | (m) | 18.70× |
| 2020-09-30 | $133.42M | $20.12M | $129.42M | (m) | (m) | (m) | $639.00K | (m) | 6.63× |
| 2020-06-30 | $23.95M | $8.27M | $21.34M | (m) | (m) | (m) | $632.00K | (m) | 2.90× |
| 2020-03-31 | $31.18M | $9.25M | $29.60M | (m) | (m) | (m) | $628.00K | (m) | 3.37× |
| 2019-12-31 | $40.59M | $13.25M | $37.42M | (m) | $2.00M | (m) | $3.18M | (m) | 3.06× |
| 2019-09-30 | $47.98M | $24.43M | $45.88M | $0.00 | $880.00K | (m) | $1.59M | (m) | 1.96× |
| 2019-06-30 | $58.60M | $24.31M | $55.86M | $0.00 | $1.49M | (m) | $1.66M | (m) | 2.41× |
| 2019-03-31 | $69.90M | $26.34M | $59.11M | $7.99M | $2.04M | (m) | $1.84M | (m) | 2.65× |
| 2018-12-31 | $81.00M | $24.95M | $55.67M | $22.92M | $1.67M | (m) | $1.52M | (m) | 3.25× |
| 2018-09-30 | $89.50M | $26.38M | $49.30M | $37.82M | $1.42M | (m) | $803.00K | (m) | 3.39× |
| 2018-06-30 | $97.11M | $24.81M | $46.73M | $47.72M | $1.20M | (m) | $1.66M | (m) | 3.91× |
| 2018-03-31 | $35.23M | $22.96M | $25.70M | $6.70M | $1.60M | (m) | $3.08M | (m) | 1.53× |
| 2017-12-31 | $42.38M | $11.19M | $28.27M | $12.69M | $830.00K | (m) | $1.35M | (m) | 3.79× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |